US FOR-PROFIT MAIL ORDER PHARMACY
US pharmaceutical sales through for-profit mail order will more than double from $4.8 billion in 1993 to $11.1 billion in 1997, forecasts a new study from Frost & Sullivan.
The share of prescription drug market revenues generated by for-profit mail order will rise during 1993-97 from 8% to over 14%, it says. While growth rates in revenue terms will fall during the 1990s due to reduced drug price inflation and loss of patient protection by top-selling drugs, the aging population will support growth.
Mail-order pharmacy doubled its share of the market between 1988 and 1992, with revenues rising 31% in the latter year alone to make it the fourth drug distribution channel in the USA behind chain drug stores, independent pharmacies and hospitals. The three largest mail-order companies control 72% of for-profit sales, says the study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze